REBIRTH Members

Köhl, Ulrike

Köhl, Ulrike, Prof. Dr. rer. nat.

Head of

Zelltherapeutika - GMP core facility, Integrated Research and Treatment Center Transplantation IFB-Tx, MHH


Biosketch:

U. Köhl (*1963), MD, PhD, is W3 professor for ‘Cellular Therapeutics’ at MHH and head of the Fraunhofer Institute of ‘Cellular Therapeutic and Immunology’ (Leipzig). Leading the central GMP core facility of MHH, she is responsible for the development and manufacturing of Advanced Therapy Medicinal Products (ATMPs) ranging from stem cells, gene-manipulated effector cells, up to iPS cells. Her recent research focuses on primary human NK cells including chimeric antigen receptors (CAR) expressing NK cells for both cancer retargeting and tolerance induction in regenerative medicine.

Biography / About

Date of Birth:March, 1963
Function:Full (W3) Professor and Head of the Institute of Cellular Therapeutics; Hannover Medical School (MHH)

Education:

07/1987Diploma in Biology (Microbiology/Pharmacology/Biochemistry), University Frankfurt, Germany
09/1995Thesis (PhD) in Pharmacology (Prof. Dr. Dr. E. Mutschler), University Frankfurt
08/2006First qualification in primary care, Medicine, University Frankfurt
07/2008Post-doctoral lecturing qualification (Habilitation) and Venia Legendi Experimental Medicine, University Frankfurt
05/2012Professor (W3) for Celluar Therapeutics, MHH

Academic appointments and Research posts:

08/1987 - 11/1995 Scientist, Pharmacokinetics, Paediatric Haematology, University Frankfurt
12/1995 - 08/1996 Post-doctoral fellow, MD Anderson Cancer Center, Section of Molecular Cell Therapy, Houston, TX, USA
09/1996 - 12/1999 Senior scientist, Stem cell laboratory, University Hospital Frankfurt
01/2000 - 04/2012 Head, Laboratory of Stem Cell Transplantation and Immunotherapy, Paediatric Haematology and Oncology, University Hospital, Frankfurt
09/2005 - 04/2012 Head (steering committee) graduate school “Biologicals”, University Frankfurt
01/2008 - 06/2010 Acting chair, Laboratory of Haematology and Coagulation, University Frankfurt
Since 05/2012Full professor for cellular therapeutics, MHH

Other professional activities:

Since 01/2013Qualified person (QP, §14 AMG), dep. head quality control (§12 AMWHV)

Awards and Prizes:

10/1993Scientific award, Academic Ziekenhuis, Amsterdam, Netherland
1995 - 1996Postdoctoral award of the Dr. Mildred-Scheel Stiftung for cancer research
05/1999Scientific “Israeli-German bi-national” prize of the GPOH, Eilat, Israel
09/2005Gutermuth prize for the development of new cell-based therapies

Major research interests:

  • Advanced Therapy Medicinal Products
  • Redirected NK cells
  • Immune escape mechanism
  • Immune reconstitution
  • Regeneration in transplantation

Furthemore:

U. Köhl is a member of numerous national and international societies and is serving as a reviewer for both the European Medicine Agency (EMA) and the European commission.

Selected Publications:

  1. Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, Marburger M, Quaiser A, Goudeva L, Arseniev L, Kaiser A, Glienke W, Köhl U. Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs. Hum Gene Ther. 2016.
  2. Huenecke S, Bremm M, Cappel C, Esser R, Quaiser A, Boenig H, Jarisch A, Soerensen J, Klingebiel T, Bader P, Köhl U. CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation fulfills the demands of an optimized graft composition. Tranfusion. 2016. DOI: 10.1111/trf.13694
  3. Köhl U, Kaberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. OncoImmunology. 2016. 11;5(4):e1115178. eCollection
  4. Klöß S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, Glienke W, Seitz O, Köhl U. Increased sMICA and TGF-b1 levels in HNSCC patients potentially impair NKG2D-dependent functionality of activated NK cells. OncoImmunology. 2015. 29;4(11):e1055993. eCollection
  5. Suerth JD, Morgan M, Klöß S, Heckl D, Neudörfl C, Falk C, Köhl U, Schambach A. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med. 2016. 94(1):83-93. DOI: 10.1007/s00109-015-1327-6.
  6. Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, Klöß S, Arseniev L, Aleksandrova K, Maecker-Kolhoff B, Blasczyk R, Köhl U*, Eiz-Vesper B* (*equal contribution). Rapid generation of clinical-grade antiviral T cells: Selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. J Translational Medicine. 2014. 16;12(1):336.
  7. Stern M, Passweg RJ, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, Köhl U. Preemptive Immunotherapy with Purified Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers. Bone Marrow Transplantation. 2013. 48(3):433-8. doi: 10.1038/bmt.2012
  8. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Petznek H, Kontermann R, Köhl U, Johnston IC, Keinänen K, Müller UC, Hohenadl C, Monyer H, Cichutek K, Buchholz CJ. Specific gene transfer to neurons, endothelial cells and stem cells: A flexible targeting system for lentiviral vectors. Nat Meth. 2010. 7(11):929-35
  9. Stein S, Ott M, Schulze-Strasser S, Jauch A, Schmid M, Schwäble J, Glimm H, Köhl U, Kühlcke K, Schlegelberger B, Trasher A, Hoelzer D, Seger R, von Kalle C, Grez M. Genomic instability and myelodysplasia with monosomy 7 caused by EVI1 activation after gene therapy for chronic Granulomatous Disease. Nature Medicine. 2010. 16 (2):198-204
  10. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Köhl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006. 12:401-409


[back to listing]
test
This website uses cookies and the web analytics service Google Analytics. Click here for further information on privacy.
I agree